Lviv clinical bulletin 2022, 3(39)-4(40): 21-25

https://orcid.org/10.25040/lkv2022.03-04.021

Prostaglandin E2 in the Blood Serum of Patients with Gastroduodenal Erosive-Ulcerative Lesions with and without Comorbid Hypertension

Posted onAuthorAdminЗалишити коментар / Leave a comment

Ye. Sklyarov1, A. Chetaykina1, M. Mbarki2, O. Kapustinsky1

1Danylo Halytsky Lviv National Medical University

2République Tunisienne Ministère de la Santé

Introduction. The combination of erosive-ulcerative lesions (EUI) of the gastroduodenal zone with hypertension (HT) is a common phenomenon and is a modern medicine’s pressing issue. Taking nonsteroidal anti-inflammatory drugs (NSAIDs), including by patients with HT, is accompanied by prostaglandin synthesis suppression due to cyclooxygenase inhibition and results in an arterial pressure increase. Moreover, it should be mentioned that patients with HT have a higher risk of gastroduodenal lesions.

The aim of the study. To explore the prostaglandin E2 content in the blood serum of patients with gastroduodenal erosive-ulcerative lesions without and with comorbid hypertension.

Materials and methods. The research involved 20 patients with gastroduodenal EUI without comorbid HT and 30 patients with gastroduodenal EUI suffering comorbid HT. All patients went through general clinical examinations, esophagogastroduodenofibroscopy (EGDFS), and stool tests to verify H.pylori infection, with prostaglandin E2 (PGE2) content in blood serum being determined.

Results. EGDFS showed that among patients with gastroduodenal EUI without comorbid HT, 25.00 % were diagnosed with gastric EUI; half of the cases (50.00 %) revealed duodenum lesions, and another 25.00 % – combined stomach and duodenum lesions. At the same time, patients with EUI combined with comorbid HT manifested more frequent (p ˂ 0.05) gastric localization of mucosal EUI (50.00 %); 16.67 % of patients had the duodenum lesions, while combined stomach and duodenum defects were observed in 33.33 %.

H. pylori infection was confirmed in 13 patients (65.00 %) with EUI without comorbid HT and in 22 examined individuals (73.33 %) with the gastroduodenal zone EUI and comorbid HT.

The endogenous PGE2 was significantly higher in patients who had only gastric mucosa and duodenum EUI without comorbid HT and amounted to 2135.79 ± 80.94 pg/ml (p ˂ 0.05), while patients with EUI and comorbid HT were tested a significantly lower PGE2 level in blood serum – 1513.55 ± 92.48 pg/ml.

At the same time, the significantly lower PGE2 level in patients with EUI and comorbid HT compared to the similar indicator in patients without it explains the differences in the EUI distribution in both groups of patients revealed during endoscopic examination. Since a significantly weakened PGE2 synthesis leads to lower bicarbonate and mucus secretion and more intensive acid production, the balance between the aggression and protection factors is upset, which contributes to the EUI emergence mainly in the stomach’s antral part.

The research has exposed no significant difference in PGE2 content in patients with duodenum mucosa EUI and those with a combination of gastric and duodenum mucosa lesions (p ˃ 0.05). Besides, the PGE2 content was tested significantly lower in patients with EUI gastric localization, than in those with combined ulcers (р ˂ 0.05). The presence or absence of H. pylori infection also did not affect the endogenous PGE2 level (p ˃ 0.05).

Conclusions. The prostaglandin E2 content in the blood serum of patients with gastroduodenal erosive-ulcerative lesions with comorbid hypertension was notably lower than in patients with erosive-ulcerative lesions of the gastroduodenal zone without comorbid hypertension. Moreover, a significant prostaglandin E2 decrease in the blood serum of patients with gastroduodenal erosive-ulcerative lesions with comorbid hypertension upsets the balance between aggression and protection factors, which contributes to the emergence of erosive-ulcerative defects, mostly in the stomach.

References

  1. Babushkina AV. About the problem of uncontrolled arterial hypertension. Ukrainian Medical Journal. 2010;5(79):73-79 (Russian)
  2. Mbarki M, Sklyarov E. Peculiarities of integrated action of proton pump inhibitors and rebamipide in the therapy of NSAID gastric disease. Actual Problems of the Modern Medicine: Bulletin of Ukrainian Medical Stomatological Academy. 2015;15(4):87-90 (Ukrainian)
  3. Sklyarova OE. Serum prostaglandin E2 levels in patients with peptic ulcer disease. Acta Medica Leopoliensia. 2013;19(4):16-19 (Ukrainian)
  4. Epstein JA, Rader DJ, Parmacek MS. Perspective: cardiovascular disease in the postgenomic eralessons learned and challenges ahead. Endocrinology. 2002;143(6):2045-2050.
  5. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D et al. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007;117(9):2496-2505.
  6. Malyutina NN, Kurnikova IA, Smirnova EN, Luzina SV, Sosnin DYu. Mathematical formula for predicting the phenotype of comorbidity – erosive-ulcerative lesions of the gastroduodenal zone and arterial hypertension in railway workers. Experimental and Clinical Gastroenterology. 2020;180(8):27-33.
  7. Mbarki M, Sklyarova O, Sklyarov E. Ultrastructure of gastric antrum mucosa in patients receiving long-term treatment with nonsteroidal antiinflammatory drugs. Wiad Lek. 2014;67(2 Pt 2):219-221.
  8. Shahin NN, Abdelkader NF, Safar MM. A Novel Role of Irbesartan in Gastroprotection against Indomethacin-Induced Gastric Injury in Rats: Targeting DDAH/ADMA and EGFR/ERK Signaling. Sci Rep. 2018;8:4280.
  9. Schmidt BM, Durao S, Toews I, Bavuma CM, Hohlfeld A, Nury E, Meerpohl JJ, Kredo T. Screening strategies for hypertension. Cochrane Database Syst Rev. 2020;5(5):CD013212.
  10. Smyth EM, Grosser T, Wang M, Yu Y, FatzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50:S423-428.
  11. Xu H, Du S, Fang B, Li C, Jia X, Zheng S et al. SMC-specific EP4 deletion exacerbates angiotensin II-induced aortic dissection by increasing vascular inflammation and blood pressure. Proc Natl Acad Sci USA. 2019;116(17):8457-8462.
  12. Xu H, Fang B, Du S, Wang S, Li Q, Jia X et al. Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis. JCI Insight. 2020;5(13):e138505.
  13. Yang T, Du Y. Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation. Am J Hypertens. 2012;25(10):1042-1049.
  14. Yang T. Role of PGE2 in blood pressure regulation. Cur Hypertens Rev. 2010;6(3):199-209.